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Abstract Allergic rhinitis and migraine remain on the list of
the most common diseases affecting adults. Migraines and
headaches due to allergic rhinitis are easily confused because
the symptoms of both conditions often overlap. Both may oc-
cur with sinus headache, nasal congestion, and lacrimation and
may worsen with weather changes and exposure to allergens.
No precise clinical definition exists for what constitutes a sinus
headache, which has always been a diagnostic dilemma.
Contrary to popular belief, headache is not a typical symptom
of rhinitis. Some studies have shown that up to 90 % of sinus
headaches are actually migraines. Nevertheless, patients with
self-diagnosed sinus headache self-treat or are treated by pri-
mary care physicians and/or otolaryngologists with medica-
tions for rhinosinusitis, ignoring the neurogenic causes of the
symptomswhenmost of these patients fulfill diagnostic criteria
for chronic migraine. Chronic migraine affects 2 % of the
general population and has a significant socioeconomic impact
on society, incurring health care costs and diminishing quality
of life; therefore, the proper diagnosis and treatment of these
headache patients should be a priority.
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Introduction
Both allergic rhinitis and chronic daily headache are common
health problems worldwide. Many patients present to head-
ache and otolaryngology clinics with self-diagnosed “sinus
headache” that ultimately is found to be chronic migraine [1,
2]. No accurate clinical definition of sinus headache exists;
this term usually is applied to patients with bilateral
headache/pressure affecting the frontomaxillary region and
accompanied by autonomic symptoms, all of which also are
present in migraine [3]. Contrary to popular belief, sinusitis is
not a common cause of this type of headache; it usually is
neurogenic in origin [4–6]. Patients with these headaches re-
port that they have received insufficient treatment for years
with medications for rhinosinusitis, usually antihistamines or
intranasal corticosteroids [7]. Because of an incorrect diagno-
sis, these patients have undergone unnecessary diagnostic
studies and surgical interventions and have not been receiving
appropriate, timely treatment [7]. Although in some cases
headache may result from sinusitis [8, 9], up to 90 % of pur-
ported sinus headaches fulfill the diagnostic criteria for mi-
graine [1, 3, 10–12]. In a study of 2991 patients presenting to
primary care physicians with sinus headache, Schreiber et al.
[13] showed that 88% of themwere diagnosed with migraine.
Sinus headache alsomay be a result of the comorbidity of both
conditions [8, 9], which is not unusual considering the high
prevalence of both diseases.
Chronic Daily Headache and Allergic Rhinitis:
Epidemiology and Burden
Chronic daily headache comprises a group of primary and
secondary headache disorders in which headache is present
on more than 15 days per month for at least 3 months [14,
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15]. Approximately, 3 to 5 % of the US population suffers
from chronic daily headaches, and the most frequent of which
is chronic migraine [14, 16–18]. This debilitating disorder
affects around 2 % of the general population and is the leading
cause of outpatient and emergency department visits [19–22].
According to the most recent health surveillance studies by the
US National Center for Health Statistics, migraine affects
roughly one in seven Americans annually, which is compara-
ble to statistics from the previous 8 years [22]. Surprisingly, a
recent US study found that the proper diagnosis of chronic
migraine is often elusive: only 20 % of patients who fulfill
the criteria are diagnosed with the disorder [23]. Several stud-
ies have provided evidence that migraine is one of the diseases
that mimic allergic rhinitis [11].
Allergic rhinitis is one of the most common chronic dis-
eases among adults in the USA and is the most common
chronic disease among children; it is estimated to affect up
to 60 million people in the USA alone [24, 25]. It affects
around one in six Americans and is responsible for 3.5 million
lost work days and 2 million lost school days per year, gener-
ating $2 billion to $5 billion in direct health expenditures
annually [26–28, 29•]. Allergies and allergic rhinitis are also
a huge health problem in Europe. According to the European
Academy of Allergy and Clinical Immunology (EAACI), 150
million Europeans, or one in five, have allergies [30, 31]. In
the pediatric population, allergy is estimated to occur in one in
three children [32]. Based on these statistics, within the next
10 years, 50 % of Europeans will be affected by allergy [33].
Because of the high prevalence and frequent coexistence of
allergic rhinitis and chronic migraine—as well as their similar
symptoms, which may lead to diagnostic errors—clinicians
must be aware of the diagnostic criteria for each condition to
make an accurate diagnosis and to apply the appropriate
treatment.
Diagnostic Criteria of Diseases Associated with Sinus
Headache: Neurology and Otolaryngology
Guidelines
There are two main systems of classification and diagnostic
criteria for sinus headache. The vast majority of sinus head-
ache patients fulfill the International Headache Society (IHS)
diagnostic criteria for migraine [1, 3, 11, 15], some of them for
chronic migraine, the most common form of chronic daily
headache. The International Classification of Headache
Disorders, third edition (ICHD-3), published by the IHS in
2013, defines chronic migraine as headache on 15 or more
days per month for more than 3 months. On at least 8 days
during the month, the headaches should have migraine fea-
tures with or without aura and/or should respond to migraine
drug treatment; in addition, a secondary cause of chronic
headache must have been ruled out [15]. Migraine may be
diagnosed after the fifth attack of headache lasting 4 to 72 h
(if untreated or unsuccessfully treated) if the headaches have
at least two of the following characteristics—a unilateral lo-
cation, a pulsating quality, moderate or severe pain intensity,
and aggravated by or causing avoidance of routine physical
activity—plus at least one of the following: nausea and/or
vomiting, photophobia, and phonophobia, not better
accounted for by another ICHD-3 diagnosis.
The ICHD-3 classification includes a group of secondary
headaches, among which is headache related to rhinosinusitis,
under the diagnoses “headache attributed to acute
rhinosinusitis” and “headache attributed to chronic or recur-
rent rhinosinusitis,” with the stipulation that accordingly
acute, chronic, or recurrent rhinosinusitis is being diagnosed.
In such cases, neurologists will diagnose headache attrib-
uted to acute, chronic, or recurrent rhinosinusitis according to
the IHS classification, whereas otolaryngologists and aller-
gists will diagnose rhinosinusitis according to the diagnostic
criteria of the American Academy of Otolaryngology–Head
and Neck Surgery (AAO-HNS) [34]. Rhinitis may be catego-
rized as allergic, nonallergic, or mixed [35•]. Allergic rhinitis
is defined as a chronic inflammatory disease of the upper
airway caused by an IgE-mediated inflammatory response of
the nasal mucous membranes after exposure to inhaled aller-
gens. It is characterized by the symptoms of rhinorrhea (ante-
rior or posterior nasal drainage), nasal congestion, sneezing,
and nasal itching (Table 1) [29•], and it often leads to sinus
headache [36]. Allergic rhinitis may be classified according to
the temporal pattern of exposure to the allergen: for example,
seasonal allergic rhinitis, in which the inflammatory response
is related to seasonal aeroallergens (e.g., tree, grass, weed
pollens), and perennial allergic rhinitis, in which the response
is related to year-round environmental aeroallergens (e.g., dust
mites, mold, pet danders, or certain occupational allergens). It
also may be classified as intermittent allergic rhinitis, in which
symptoms persist for more than 4 days per week and more
than 4 weeks per year, and persistent allergic rhinitis, in which
symptoms last more than 4 days per week and more than
4 weeks per year [37]. In addition, the latest AAO-HNS clin-
ical practice guideline for diagnosing allergic rhinitis defines a
third category: episodic allergic rhinitis, in which a patient has
an inflammatory response to something not normally encoun-
tered in his or her environment (e.g., a cat at a friend’s house)
[29•, 38]. Because both the IHS and AAO-HNS classification
systems have limitations, creating an interdisciplinary algo-
rithm for sinus headache patients should be a top priority.
Why Sinus Headache Is a Diagnostic Challenge:
Similarities and Differences
To explain why migraine and allergic rhinitis are confused
with each another, we need to consider the common
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Table 1 Diagnostic criteria for rhinosinusitis, allergic rhinitis, and migraine
Disease Classification system Criteria
Migraine without auraa ICHD-3 A. At least five attacks fulfilling criteria B–D
B. Headache attacks lasting 4–72 h when untreated or unsuccessfully treated
C. Headache has at least two of the following characteristics: unilateral location,
pulsating quality, moderate or severe pain intensity, aggravation by or causing
avoidance of routine physical activity (e.g., walking or climbing stairs)
D. During headache, at least one of the following: nausea and/or vomiting,
photophobia, and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis
Chronic migraine ICHD-3 A. Headache, tension-type–like and/or migraine-like, on 15 days/month for at
least 3 months, fulfilling criteria B and C
B. Occurring in a patient who has had at least five attacks fulfilling criteria for
migraine without or with aura
C. On 8 days/month, headache has migraine features and is relieved by a
triptan or ergot derivative
D. Not better accounted for by another ICHD-3 diagnosis
Headache attributed to chronic
or recurring rhinosinusitis
ICHD-3 A. Any headache fulfilling criterion C
B. Clinical, nasal endoscopic, and/or imaging evidence of current or past
inflammatory process within the paranasal sinuses
C. Evidence of causation demonstrated by at least two:
1. Headache has developed in temporal relation to the onset of chronic
rhinosinusitis
2. Headache waxes and wanes in parallel with the degree of sinus congestion,
drainage, and other symptoms of chronic rhinosinusitis
3. Headache is exacerbated by pressure applied over the paranasal sinuses
4. In the case of unilateral rhinosinusitis, headache is localized ipsilateral to it
D. Not better accounted for by another ICHD-3 diagnosis
Headache attributed to acute
rhinosinusitis
ICHD-3 A. Any headache fulfilling criterion C
B. Clinical, nasal endoscopic, and/or imaging evidence of acute rhinosinusitis
C. Evidence of causation demonstrated by at least two:
1. Headache has developed in temporal relation to the onset of rhinosinusitis
2. Either of the following:
(a) Headache has significantly worsened in parallel with worsening
of the rhinosinusitis
(b) Headache has significantly improved or resolved in parallel with
improvement in or resolution of the rhinosinusitis
3. Headache is exacerbated by pressure applied over the paranasal sinuses
4. In the case of unilateral rhinosinusitis, headache is localized ipsilateral to it

















Allergic rhinitis AAO-HNS An IgE-mediated systemic inflammatory disease with symptoms of rhinorrhea
(anterior or posterior nasal drainage), nasal congestion, nasal itching, and
sneezing in response to an allergen
aMigraine with aura is characterized primarily by the transient focal neurologic symptoms that usually precede or sometimes accompany the migraine
headache
b Two major factors or one major factor and one minor factor are required to diagnose rhinosinusitis
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symptoms, pathophysiology, and social beliefs regarding si-
nus headache [38]. Both disorders may have the same triggers
(e.g., weather changes, inhaled irritants) affecting the same
parts of the body (e.g., forehead, nose, frontomaxillary area,
ethmoid area, space behind and around the eyes) [3]. Migraine
and allergic rhinitis also may have similar symptoms, such as
nasal congestion, rhinorrhea, pressure/pain behind the eyes, a
feeling of fullness in the head, and lacrimation [39]. These
cranial autonomic symptoms accompany migraine in a signif-
icant percentage of cases, leading to diagnostic errors [40–44].
It is commonly known that these cranial symptoms typically
are associated with trigeminal autonomic cephalalgias (TACs)
and are critical components of the diagnostic criteria for
TACs. Autonomic nervous system dysfunction also is a pri-
mary characteristic of migraine [43, 44]. In conclusion, iden-
tifying cranial autonomic symptoms in migraine is crucial in
the differential diagnosis of TACs and allergic rhinitis [45]. In
a study of 177 patients with migraine, Barbanti et al. [42]
found that 45.8 % had autonomic symptoms such as
rhinorrhea, nasal congestion, lacrimation, conjunctival injec-
tion, and eyelid edema during migraines. Similarly, Guven
et al. [46] examined 186 patients with episodic migraine and
reported that most developed cranial autonomic symptoms
with their headaches. They also noted that autonomic symp-
toms were more common in menstruation-related migraines.
Thus, they hypothesized that hormonal factors might play a
role in triggering the trigeminal–autonomic reflex pathway
[46]. Although the autonomic symptoms in migraine usually
are bilateral, in some cases they may be unilateral [42], which
must be kept in mind to avoid confusing migraine with TACs.
Also, in chronic migraine, cranial autonomic symptoms occur
very frequently. Riesco et al. [47] analyzed a group of 100
patients with chronic migraine and found that the most fre-
quent autonomic symptoms were lacrimation (in 49 % of pa-
tients), conjunctival injection (in 44 %), eyelid edema (in
39 %), ear fullness (in 30 %), and nasal congestion (in
20 %). However, despite all these data showing that autonom-
ic symptoms frequently are a concomitant clinical feature of
migraine, these symptoms are not included in the current di-
agnostic criteria.
Another common feature of allergic rhinitis and mi-
graine is their seasonal exacerbation in the spring, fall,
and summer months as a result of allergic triggers [35•,
39, 48, 49]. A study from South Korea conducted be-
tween 2005 and 2013 showed that 13.5 % of migraine
patients reported seasonal exacerbations [48]. Moreover,
the costs of migraine treatment are higher during allergy
season [49], because many people with migraine experi-
ence an increase in headache intensity and frequency due
to coexisting allergic rhinitis [50]. Furthermore, ocular
and nasal symptoms in allergic rhinitis may vary from
day to day, depending on the allergen concentration in
the atmosphere [51, 52].
To avoid a misdiagnosis, it is important to realize that the
pain characteristics of each condition may differ. Patients de-
scribe sinus-related pain as dull and pressure-like; usually bi-
lateral; located in the maxillary, glabellar, periorbital, or fron-
tal regions of the skull; and worse in the morning. Those with
migraine, on the other hand, usually describe the pain as
throbbing or stabbing, mostly unilateral, moderate to severe
in intensity, located in the temporal or retro-orbital area, and
not worse during a particular time of day [10].
With regard to age at onset, slight differences exist between
allergic rhinitis and migraine. Four of five patients with aller-
gic rhinitis develop symptoms before their 20s, with 40 %
becoming symptomatic by the age of 6 years [24]. Migraine
is a disease affecting mostly women of reproductive age [22],
with data from the American Migraine Study II indicating that
its peak prevalence occurs between the ages of 25 and 55 years
[11]. Furthermore, although migraine headache symptoms in-
clude nasal discharge, it is not thick and purulent as is typical
in rhinogenic headache. Fever, chills and sweats, itchy nose,
and itchy eyes also are typical in rhinitis but not in migraine
[53, 54]. Physical examination findings such as dark areas
under the eyes, conjunctivitis, and eczema, as well as the
presence of another allergic or atopic disease, such as asthma,
suggest allergic rhinitis [55]. On the other hand, nausea and
vomiting; hypersensitivity to light, sound, and smells; and
typical migraine pain lasting 4 to 72 h, occurring at least 8 days
per month, and responsive to triptans support the diagnosis of
chronic migraine [15].
Comorbidity and Pathophysiology
In a retrospective study conducted from 2010 to 2012 in 211
patients presenting to otolaryngologists with symptoms of si-
nus pressure, pain, or headache, nearly half the patients
(48.82 %) were diagnosed as having primary headache disor-
ders. In this study, neurologic and rhinologic disease coexisted
in around 28 % of the patients [8]. In a questionnaire study
among 30,000 Norwegians aged 30 to 44 years, with a 71 %
response rate, Aaseth et al. [56] found that those with chronic
rhinosinusitis had a ninefold increased risk of chronic head-
aches compared with the general population. Similarly, Ku
et al. [57] reported that migraine was diagnosed much more
often in allergic rhinitis patients (occurring in 34 %) than in
the control group without allergic rhinitis (occurring in 2 %).
In patients with allergic rhinitis, the development and course
of migraine may have a significant allergic component [58].
However, in their study of 536 allergic rhinitis patients,Martin
et al. [59] found no association between the prevalence of
migraine and the degree of allergic sensitization, although
they observed a significant age/immunotherapy interaction.
In this study, migraine headaches were less prevalent, fre-
quent, and disabling after immunotherapy and in lower
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degrees of atopy. Similarly, in a prospective study,
Theodoropoulos et al. [58] observed that interictal serum C-
reactive protein levels declined and the severity of migraines
and rhinitis decreased during sublingual immunotherapy.
Immunotherapy induces tolerance to specific allergens
through two mechanisms of action: by altering cytokine re-
sponses of T helper cells and by promoting IgG and IgA,
antibodies that block the binding of IgE to mast cells
[59–61]. Data from another study revealed a correlation be-
tween serum IgE levels and the severity and frequency of
migraines: patients with higher levels of IgE had more severe
headaches than those with lower levels of IgE [61]. These data
support the hypothesis that migraine severity and disability
depend on coexisting allergic rhinitis, which might provide
an interesting rationale for treatments targeted at reducing mi-
graine intensity and disability among patients with coexisting
allergy and migraine; however, further investigation is
needed.
The underlying mechanisms for explaining the association
between allergic rhinitis and migraine are complex and not
well understood. One hypothesis is that a link between auto-
nomic dysfunction and mast cell degranulation or shared
genes is responsible for these diseases [35•]. In the pathogen-
esis of allergic rhinitis, allergens interact with mucosal mem-
branes in the nasal cavity and paranasal sinuses, activating
inflammatory cell response [52]. Antigen-presenting cells in
the epithelium and lamina propria of the nasal mucosa break
the allergens down into small peptides that are presented by
MHC class II molecules to T lymphocytes (T cells) [62]. The
T cells produce specific cytokines that further differentiate T
cell precursors, activating eosinophils and the synthesis and
excretion of IgE by B lymphocytes [63]. Two phases of aller-
gic response may be significant. The early phase includes
binding of IgE to specific receptors located on the mast cells
and basophils, which stimulates these cells to excrete hista-
mine, proteinases, serotonin, leukotrienes, prostaglandins, and
other chemicals [59, 64, 65]. This period represents the begin-
ning of the acute stage of allergic rhinitis, with symptoms such
as sneezing, runny and itchy nose, swelling, and itchy and
watery eyes. Excessive mucus production in the nasal and
sinus cavities causes the feeling of sinus pressure and pain
[64]. The late phase of allergic reaction occurs 4 to 8 h after
exposure to an allergen and is associated with constitutional
symptoms such as fatigue, malaise, headache, and irritability
[57, 64, 66, 67].
The pathogenesis of migraine is complex and involves re-
curring activation and sensitization of the trigeminovascular
pathway, intracranial arterial dilatation, neurogenic inflamma-
tion, and resultant structural and functional changes in genet-
ically predisposed individuals [68]. In migraine pathogenesis,
the most affected part of the nervous system is the
trigeminovascular system, consisting of nociceptive trigemi-
nal sensory afferents. These neurons originate in the
trigeminal ganglion [69] and extend to the dura through three
major branches: the ophthalmic (V1), maxillary (V2), and
mandibular (V3) [68]. All three divisions supply somatosen-
sory innervation to specific regions of the face, head, and nasal
and sinus cavities. Innervation of the anterosuperior part of the
nasal cavity is provided by V1, whereas the posteroinferior
part is innervated by V2 [70]. The facial parasympathetic ef-
ferents innervate the lacrimal glands, nasal and sinus mucosa,
and cerebral blood vessels and are responsible for autonomic
cranial symptoms, including the conjunctival injection, lacri-
mation, nasal congestion, and rhinorrhea that accompany mi-
graine attacks [71, 72]. Certainly, it is well established that
allergens can activate trigeminal nociceptors by releasing in-
flammatory chemicals from dural mast cells, triggering a mi-
graine attack [73–75]. Evidence also exists that histamine may
induce migraine attacks by increasing the level of nitric oxide
(NO) [36], which is believed to promote migraine attacks
through its vasodilator effects via H1 and H2 receptors; this
is another inflammatory mediator found in both allergic rhini-
tis and migraine [57, 76, 77]. Inflammation plays an important
role in the complex pathogenesis of migraine as well as of
allergic rhinitis [58, 78]. In some patients, migraines are trig-
gered by stress or extended physical activity, both of which
lead to production of pro-inflammatory cytokines [79].
Obesity, which is associated with a constant state of low-
grade systemic inflammation, is believed to be a major risk
factor for chronification of episodic migraine and is an exac-
erbating factor in migraine headaches [80–83]. All these ana-
tomic and physiologic relationships help explain why differ-
entiating allergic rhinitis from migraine is a diagnostic chal-
lenge. However, the reason asthma, allergic rhinitis, and other
atopic disorders are comorbidities of migraine in a substantial
percentage of cases remains unclear and requires further
investigation.
Conclusions
Although migraine and rhinitis are not life-threatening dis-
eases, they both carry a huge socioeconomic burden world-
wide, affecting work and daily activities. Both have a high
worldwide prevalence, have a high rate of coexistence, and
significantly decrease quality of life and productivity by caus-
ing fatigue, headache, cognitive impairment, and sleep prob-
lems, particularly when they coexist in the same individual
[39]. A common theme in studies of migraine and allergic
rhinitis is that their similar symptomatology makes them dif-
ficult to differentiate. Bearing in mind that these two condi-
tions may coexist in an individual, allergists and otolaryngol-
ogists should consider migraine as a diagnosis in their sinus
headache patients, whereas neurologists should consider a na-
sal or sinus pathology as the cause of headaches in their pa-
tients. Therefore, physicians must obtain an accurate medical
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history, focusing their attention on symptoms (i.e., duration,
exposures, magnitude of reaction, patterns, and chronicity),
triggers, seasonal variations, environmental influences, aller-
gies, past medical history (e.g., trauma, family, and treatment
histories), and current treatments. Once a patient receives the
correct diagnosis, the physician can focus on minimizing ex-
acerbating factors and offering adequate treatment. In mi-
graine patients with coexisting allergic rhinitis whose mi-
graines are exacerbated by rhinitis, managing the allergies
may reduce the frequency of migraines. Determining the ap-
propriate treatment may substantially improve the quality of
life of sinus headache patients and reduce the global burden of
chronic migraine and allergic rhinitis [83, 84].
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